Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, placebo-controlled study to assess the safety and tolerability of a cell-derived influenza vaccine in healthy adults aged greater than or equal to 18 years and less than or equal to 49 years.

Next Previous
Trial Profile

Randomized, double-blind, placebo-controlled study to assess the safety and tolerability of a cell-derived influenza vaccine in healthy adults aged greater than or equal to 18 years and less than or equal to 49 years.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Solvay Pharmaceuticals

Most Recent Events

  • 23 Apr 2010 Trial sponsor and affiliate changed from Solvay Pharmaceuticals to Abbott Laboratories as Solvay Pharmaceuticals is acquired by Abbott Laboratories.
  • 29 Jun 2008 Actual study completion date is now 1 May 2008 as reported by ClinicalTrials.gov.
  • 19 Feb 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top